Transgenic models for proliferative and hyperfunctional thyroid diseases

Experimental and Clinical Endocrinology and Diabetes

Volumn 104, Issue SUPPL. 3, 1996, Pages 43-46

  Ledent, C ^a   Coppee F ^a   Dumont, J E ^a   Vassart, G ^a   Parmentier, Marc ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Constitutive activity; G protein coupled receptor; Retinoblastoma susceptibility gene; Thyroid cancer; Transgenic mice

Indexed keywords

ADENOSINE A2 RECEPTOR; CHLORAMPHENICOL ACETYLTRANSFERASE; CYCLIC AMP; ONCOPROTEIN; THYROGLOBULIN; THYROTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL PROLIFERATION; CONFERENCE PAPER; GOITER; HYPERTHYROIDISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; THYROID ADENOMA; THYROID CANCER; THYROID CELL; THYROID DISEASE; THYROID FUNCTION; TISSUE SPECIFICITY; TRANSGENE; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; WART VIRUS;

EID: 0029753696     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1211683     Document Type: Conference Paper

References (20)

1. Adams JM, Cory S: Transgenic models of tumor development. Science 254: 1161-1167, 1991
2. Christophe D, Vassart G: The thyroglobulin gene: evolutionary and regulatory issues. Trends Endocrinol Metab 1: 351-356, 1990
3. Dumont JE, Lefort A, Libert F, Parmentier M, Raspe E, Reuse S, Maenhaut C, Roger P, Corvilain B, Laurent E, Mockel J, Lamy F, Van Sande J, Vassart G: Transducing systems in the control of human thyroid cell function, proliferation, and differentiation. Adv Exp Med Biol 261: 357-372, 1990
4. Duprez L, Parma J, Van Sande J, Allgeier A, Leclere J, Schvartz C, Delisle MJ, Decoulx M, Orgiazzi J, Dumont J, Vassart G: Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 7: 396-401, 1994
5. Ledent C, Parmentier M, Vassart G: Tissue specific expression and methylation of a thyroglobulin-CAT gene in transgenic mice. Proc Natl Acad Sci USA 87: 6176-6180, 1990
6. Ledent C, Dumont JE, Vassart G, Parmentier M: Thyroid adenocarcinomas secondary to tissue specific expression of SV40 large T antigen in transgenic mice. Endocrinology 129: 1391-1401, 1991
7. Ledent C, Dumont JE, Vassart G, Parmentier M: Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism. EMBO J 11: 537-542, 1992
8. Ledent C, Marcotte A, Dumont JE, Vassart G, Parmentier M: Differentiated carcinomas develop as a consequence of the thyroid specific expression of a thyroglobulin-human papillomavirus type 16 E7 transgene. Oncogene 10: 1789-1797, 1995
9. Libert F, Parmentier M, Lefort A, Dinsart C, Van Sande J, Maenhaut C, Simons MJ, Dumont JE, Vassart G: Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science 244: 569-572, 1989
10. McKenzie JM, Zakarija M: The clinical use of thyrotropin receptor antibody measurements. J Clin Endocrinol Metab 69, 1093-1096, 1989
11. Maenhaut C, Van Sande J, Libert F, Abramowicz M, Parmentier M, Vanderhaeghen JJ, Dumont JE, Vassart G, Schiffmann S: RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. Biochem Biophys Res Commun 173: 1169-1178, 1990
12. Michiels FM, Caillou B, Talbot M, Dessarps Freichey F, Maunoury MT, Schlumberger M, Mercken L, Monier R, Feunteun J: Oncogenic potential of guanine nucleotide stimulatory factor alpha subunit in thyroid glands of transgenic mice. Proc Natl Acad Sc. USA 91: 10488-10492, 1994
13. Parma J, Duprez L, Van Sande J, Cochaux C, Gervy C, Mockel J, Dumont J, Vassart G: Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365: 649-651, 1993
14. Parma J, Van Sande J, Swillens S, Tonacchera M, Dumont JE, Vassart G: Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3′, 5′-monophosphate and inositol phosphate-Ca++ cascades. Mol Endocrinol 9: 725-733, 1995
15. Santelli G, de Franciscis V, Portella G, Chiappetta G, D'Alessio A, Califano D, Rosati R, Mineo A, Monaco C, Manzo G, Pozzi L, Vecchio G: Production of transgenic mice expressing the Ki-ras oncogene under the control of a thyroglobulin promoter. Cancer Res 53: 5523-5527, 1993
16. Skinner CA, Kelly D, Kao LR, Nayfeh SN, Popko B, Chae CB: Thyroid-specific and hormone-dependent expression of rat thyroglobulin promoter fused with bacterial chloramphenicol acetyltransferase gene in transgenic mice. Mol Cell Endocrinol 90: 33-38, 1992
17. Stringer BMJ, Wynford-Thomas D: Control of thyroid follicular cell proliferation-molecular aspects. In Thyroid Tumours: Molecular Basis of Pathogenesis. D. Wynford-Thomas and E.D. Williams, editors. Churchill Livingstone, London. 91-122, 1989
18. Wallace H, Ledent C, Vassart G, Bishop JO, Al-Shawi R: Specific ablation of thyroid follicle cells in adult transgenic mice. Endocrinology 129: 3217-3226, 1991
19. Wallace H, McLaren K, Al-Shawi R, Bishop JO: Consequences of thyroid hormone deficiency induced by the specific ablation of thyroid follicle cells in adult transgenic mice. J Endocrinol 143: 107-120, 1994
20. Weintraub BD, Gershengorn MC, Kourides JA, Fein H: Ann. Intern. Med. 95, 339-351, 1981